Science Sparks @ ACTREC
18thNovember 2024Publications
- 1. Goyal P, Kumar M, Kiran M, Srivastava S, Roy S, Garg S, Salunke S, Lader S, Quadir K, Ansari A, Fatima Z, Qayyumi B, Tuljapurkar V, Chaturvedi P (2024). Optimizing Surgical Margins in Oral Cancer without Frozen Section: A single center retrospective study. European Journal of Surgical Oncology.
- 2. Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC, Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A, Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah A, Menon N, Ghosh S, Choudhury S, Shah S, Agrawal A, Lakshminarayanan N, Kumar A, Gopalakrishna A (2024). FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study. Neuroradiology. Thesis
Bhawna Singh. 2024. Elucidating the role of BCCIP in cancer pathogenesis and development of resistance. (LIFE09201804008) (Guide: Dr. Shilpee Dutt)
Video of the Week
Building Knowledge on childhood cancer through collaboration of cancer registries
Upcoming Events
Pre Conference Workshop November 28, 2024 Conference 29-30th November 2024
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai & CIDCO Convention Centre, Vashi, Navi Mumbai.
11th - 12th December, 2024
At ACTREC, Tata Memorial Centre, Kharghar.
20th-22nd January 2025.
At NIMHANS Convention Centre, Bengaluru.
Do You Know?
In 1958, scientist developed 5-fluorouracil (5-FU), a chemotherapy drug used to treat many cancers. It is a first-line treatment for colon cancer.
Cancer News
National Cancer Institute, 11/11/2024
In experiments in human lung cancer cell lines and mouse models of lung cancer, the researchers found that combining RAS inhibitors with different targeted cancer drugs that reactivate DLC1’s tumor suppressor activity had potent activity against cancer more potent than that of RAS inhibitors alone...
MedicalXpress, 12/11/2024
In a total of 127 patients, the two-year disease-free survival rate was 52% for the control group and 67% for the experimental group, indicating that the addition of pembrolizumab reduced recurrence or death for patients...
News-Medical, 13/11/2024
In the study, neurosurgeons examined tumor samples from 220 patients with high-grade and low-grade diffuse glioma, the most common type of adult brain tumor. They found that 3.8% of patients for whom FastGlioma had been applied had remaining high-risk tissue...
© 2024 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)